NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00173-0915-61 | 00173-0915 | Niraparib | ZEJULA | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 27, 2023 | In Use | |
00310-0668-60 | 00310-0668 | Olaparib | Lynparza | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use | |
69660-0202-91 | 69660-0202 | Rucaparib | Rubraca | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | May 1, 2017 | Jul 31, 2025 | In Use |
69660-0203-91 | 69660-0203 | Rucaparib | Rubraca | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec 19, 2016 | Jul 31, 2025 | In Use |
00069-0454-30 | 00069-0454 | Talazoparib | Talzenna | 0.35 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
00069-0546-30 | 00069-0546 | Talazoparib | Talzenna | 0.5 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
00173-0912-61 | 00173-0912 | Niraparib | ZEJULA | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 27, 2023 | In Use | |
00069-0655-30 | 00069-0655 | Talazoparib | Talzenna | 0.75 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
63539-0295-30 | 63539-0295 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec 10, 2018 | In Use | |
00069-0296-30 | 00069-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | In Use | |
00310-0679-12 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use | |
00310-0679-60 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use | |
00310-0679-95 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 31, 2017 | In Use | |
00310-0657-58 | 00310-0657 | Olaparib | Lynparza | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec 24, 2014 | Mar 31, 2020 | No Longer Used |
63539-0051-30 | 63539-0051 | Talazoparib | Talzenna | 0.5 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 21, 2023 | In Use | |
00069-1751-30 | 00069-1751 | Talazoparib | Talzenna | 0.75 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jan 31, 2022 | In Use | |
00069-1195-30 | 00069-1195 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | In Use | |
00069-0757-30 | 00069-0757 | Talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
69656-0103-61 | 69656-0103 | Niraparib | Zejula | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jul 1, 2020 | Aug 31, 2024 | No Longer Used |
69656-0103-90 | 69656-0103 | Niraparib | Zejula | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Mar 27, 2017 | May 31, 2022 | No Longer Used |
55513-0078-01 | 55513-0078 | Talimogene Laherparepvec | Imlygic | 1000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
55513-0079-01 | 55513-0079 | Talimogene Laherparepvec | Imlygic | 100000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
51079-0692-03 | 51079-0692 | Bicalutamide | Bicalutamide | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct 30, 2009 | Mar 31, 2014 | No Longer Used | |
51991-0560-01 | 51991-0560 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Nov 16, 2010 | Jul 31, 2013 | No Longer Used |
65841-0613-05 | 65841-0613 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jul 6, 2009 | In Use |
Found 11120 results — Export these results